Double-blind, randomised, placebo-controlled trial of levetiracetam fo
Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Levetiracetam
Synaptic vesicle glycoprotein 2A modulator|Voltage-gated N-type calcium channel alpha-1B subunit blocker
What it measured
Main measures
Patients verbal score of pain relief (complete, good, moderate, slight, no, worse) at the end of each treatment period
Pain
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: 1.The diagnoses multiple sclerosis verified by neurologist Exclusion: 1.additional cause of pain
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To determine if levetiracetam will relieve central neuropathic pain in multiple sclerosis
Loading reviews and guidelines…
Related trials
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiot
Phase 3 · Not yet recruiting
Still running
- A study to asses the effects of Nabiximols on spasticity associated wi
Phase 3 · Completed
No results found
- Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Me
Phase 3 · Stopped early
Stopped
- Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinica
Phase 3 · Completed
Missed its main goal
- Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Ther
Phase 3 · Stopped early
Stopped
History
Started
May 2006